Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have earned an average recommendation of "Reduce" from the nine analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $26.50.
IART has been the subject of several analyst reports. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Morgan Stanley boosted their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a report on Monday, July 15th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a report on Monday. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Finally, JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a research note on Tuesday, July 30th.
Check Out Our Latest Report on IART
Integra LifeSciences Price Performance
IART traded up $0.11 during midday trading on Friday, hitting $19.87. The stock had a trading volume of 482,731 shares, compared to its average volume of 1,103,766. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The business has a fifty day moving average of $19.03 and a 200 day moving average of $25.57. The company has a market cap of $1.57 billion, a P/E ratio of 39.74, a price-to-earnings-growth ratio of 0.62 and a beta of 1.09.
Ad ProsperityPub
Automated options just got reloaded
When I first discovered my Automated Options strategy, I thought it would be the best income trade I ever worked with.
I mean, this strategy has shown the power to pay out $1,250 per trade with just $2,500 invested…
And if everything works out correctly, the trade closes out automatically, allowing traders to close their laptops and NEVER bother looking at their accounts!
But you see, thanks to a NEW set of data…
And an overnight market phenomenon that dates all the way back to the early ‘90s…
I’ve discovered a new way to amplify our Automated Options results in just a fraction of the time!
I’m calling it the Overnight Income Project, and I want to invite ALL my students, regardless of whether they’ve traded Automated Options before, to join me and Graham Lindman LIVE on Monday to learn all about it.
Tap here to save your seat at this briefing
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the firm earned $0.71 EPS. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.
Institutional Trading of Integra LifeSciences
A number of hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. grew its stake in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC increased its holdings in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after buying an additional 425 shares in the last quarter. Valley National Advisers Inc. bought a new position in Integra LifeSciences during the 1st quarter valued at about $63,000. Canada Pension Plan Investment Board purchased a new stake in shares of Integra LifeSciences during the 2nd quarter valued at about $114,000. Finally, Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences during the first quarter valued at approximately $143,000. 84.78% of the stock is owned by institutional investors.
Integra LifeSciences Company Profile
(
Get Free ReportIntegra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
